Optimizing antiinfective transition therapy in community-acquired pneumoniaQUINTILIANI, Richard.Pharmacotherapy. 2001, Vol 21, Num 7, issn 0277-0008, 34 p., 2Serial Issue

Regulation of VanA- and VanB-type glycopeptide resistance in enterococciARTHUR, Michel; QUINTILIANI, Richard JR.Antimicrobial agents and chemotherapy. 2001, Vol 45, Num 2, pp 375-381, issn 0066-4804Article

New directions in antiinfective therapy for community-acquired pneumonia in the emergency departmentMORAN, Gregory J.Pharmacotherapy. 2001, Vol 21, Num 7, pp 95S-99S, issn 0277-0008, 2Article

A controlled trial of a critical pathway for treating community-acquired pneumonia : The CAPITAL studyFEAGAN, Brian G.Pharmacotherapy. 2001, Vol 21, Num 7, pp 89S-94S, issn 0277-0008, 2Article

Intravenous-to-oral transition therapy in community-acquired pneumonia : The INOVA Health System experienceMILKOVICH, Gary.Pharmacotherapy. 2001, Vol 21, Num 7, pp 83S-88S, issn 0277-0008, 2Article

The use of fluoroquinolones as antiinfective transition'therapy agents in community-acquired pneumoniaPRESS, Robert A.Pharmacotherapy. 2001, Vol 21, Num 7, pp 100S-104S, issn 0277-0008, 2Article

Managing antiinfective therapy of community-acquired pneumonia in the hospital setting : Focus on switch therapyRAMIREZ, Julio A.Pharmacotherapy. 2001, Vol 21, Num 7, pp 79S-82S, issn 0277-0008, 2Article

Pneumonia Due to Pseudomonas aeruginosa: Part II: Antimicrobial Resistance, Pharmacodynamic Concepts, and Antibiotic TherapySUN, Hsin-Yun; FUJITANI, Shigeki; QUINTILIANI, Richard et al.Chest (American College of Chest Physicians). 2011, Vol 139, Num 5, pp 1172-1185, issn 0012-3692, 14 p.Article

Circulating tumor necrosis factor-alpha production during the progression of rat endotoxic sepsisDAWEI XUAN; NICOLAU, David P; NIGHTINGALE, Charles H et al.Chemotherapy (Basel). 2001, Vol 47, Num 3, pp 194-202, issn 0009-3157Article

Minimal interaction between gatifloxacin and oxycodoneGRANT, Edward M; NICOLAU, David P; NIGHTINGALE, Charles et al.Journal of clinical pharmacology. 2002, Vol 42, Num 8, pp 928-932, issn 0091-2700Article

Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosaMCNABB, Jocarol; QUINTILIANI, Richard; NIGHTINGALE, Charles H et al.Chemotherapy (Basel). 2000, Vol 46, Num 6, pp 383-389, issn 0009-3157Article

Pharmacodynamic study of β-lactams alone and in combination with β-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible β-lactamaseCHONGHUA LI; NICOLAU, David P; LISTER, Philip D et al.Journal of antimicrobial chemotherapy (Print). 2004, Vol 53, Num 2, pp 297-304, issn 0305-7453, 8 p.Article

Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oralKUTI, Joseph L; LE, Thuy N; NIGHTINGALE, Charles H et al.American journal of health-system pharmacy. 2002, Vol 59, Num 22, pp 2209-2215, issn 1079-2082, 7 p.Conference Paper

Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactamKIM, Myo-Kyoung; XUAN, Dawei; QUINTILIANI, Richard et al.Journal of antimicrobial chemotherapy (Print). 2001, Vol 48, Num 2, pp 259-267, issn 0305-7453Article

Treatment of Serratio marcescens meningitis with prolonged infusion of meropenemNICASIO, Anthony M; QUINTILIANI, Richard; DERYKE, C. Andrew et al.The Annals of pharmacotherapy. 2007, Vol 41, Num 6, pp 1077-1081, issn 1060-0280, 5 p.Article

Lack of interaction between levofloxacin and oxycodone : Pharmacokinetics and drug dispositionGRANT, Edward M; MINGKANG ZHONG; FITZGERALD, James F et al.Journal of clinical pharmacology. 2001, Vol 41, Num 2, pp 206-209, issn 0091-2700Article

Daptomycin. CommentaryFENTON, Caroline; KEATING, Gillian M; CURRAN, Monique P et al.Drugs (Basel). 2004, Vol 64, Num 4, pp 445-458, issn 0012-6667, 14 p.Article

Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactamKIM, Myo-Kyoung; CAPITANO, Blair; MATTOES, Holly M et al.Pharmacotherapy. 2002, Vol 22, Num 5, pp 569-577, issn 0277-0008Article

Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogensOWENS, Robert C; TESSIER, Pamela; NIGHTINGALE, Charles H et al.International journal of antimicrobial agents. 2001, Vol 17, Num 6, pp 483-489, issn 0924-8579Article

Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumoniaNICOLAU, David P; MCNABB, Jocarol; LACY, Melinda K et al.International journal of antimicrobial agents. 2001, Vol 17, Num 6, pp 497-504, issn 0924-8579Article

Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patientsBUI, Khanh Q; AMBROSE, Paul G; NICOLAU, David P et al.Chemotherapy (Basel). 2001, Vol 47, Num 3, pp 153-156, issn 0009-3157Article

Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage modelDAWEI XUAN; MINGKANG ZHONG; MATTOES, Holly et al.Antimicrobial agents and chemotherapy. 2001, Vol 45, Num 3, pp 794-799, issn 0066-4804Article

Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumoniaMCNABB, Jocarol J; NIGHTINGALE, Charles H; QUINTILIANI, Richard et al.Pharmacotherapy. 2001, Vol 21, Num 5, pp 549-555, issn 0277-0008Conference Paper

Comparative Pharmacokinetics, Pharmacodynamics, and Tolerability of Ertapenem 1 Gram/Day Administered as a Rapid 5-Minute Infusion versus the Standard 30-Minute Infusion in Healthy Adult VolunteersWISKIRCHEN, Dora E; HOUSMAN, Seth T; QUINTILIANI, Richard et al.Pharmacotherapy. 2013, Vol 33, Num 3, pp 266-274, issn 0277-0008, 9 p.Article

Pharmacokinetics of Doripenem in Infected Patients Treated Within and Outside the Intensive Care UnitBHALODI, Amira A; KEEL, Rebecca A; QUINTILIANI, Richard et al.The Annals of pharmacotherapy. 2013, Vol 47, Num 5, pp 617-627, issn 1060-0280, 11 p.Article